SM Energy targets a 1x leverage ratio, prioritizing debt reduction using $1.5 billion in pro forma free cash flow and potential divestiture proceeds. Learn more about SM stock here.
Altimmune, Inc. closed a $75 million direct offering to fund Phase 3 pemvidutide trials for MASH. Learn more about ALT stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results